STVN
T3Stevanato Group S.p.A.
OverviewStevanato Group S.p.A. provides integrated solutions for pharma and healthcare. Its Biopharmaceutical and Diagnostic Solutions (BDS) segment, the primary revenu
Stevanato Group S.p.A. provides integrated solutions for pharma and healthcare. Its Biopharmaceutical and Diagnostic Solutions (BDS) segment, the primary revenue driver, offers drug containment and delivery systems like syringes and vials, particularly high-value solutions (46% of 2025 revenue) for biologics and GLP-1s. The Engineering segment supplies glass forming and inspection machinery. They serve a global customer base of pharmaceutical and biotech companies.
- What They Do (Plain English & Analogies)
- Stevanato Group is like a specialized toolkit provider for pharmaceutical companies. Imagine drug manufacturers need to put their medicines into very specific, high-quality containers (like tiny glass vials, syringes, or cartridges) and sometimes also need the devices to inject them (like auto-injectors or pen injectors). Stevanato Group makes these containers and injection devices. They also build the highly precise machines that pharmaceutical companies use to make, inspect, assemble, and package these containers and devices themselves. So, they offer both the 'packaging' and 'delivery tools' for drugs, especially complex injectable medicines like biologics, and the 'factory equipment' to produce them. They are mission-critical to the delivery of biologics, supporting new therapeutic areas, expanding global access to treatments, and improving standards of care.
- Very Brief History
- Founded in 1949 by Giovanni Stevanato as Soffieria Stella, a handmade glass laboratory in Zelarino, Italy, the company initially produced glass bottles. In 1959, it moved to Piombino Dese and later established Ompi in 1969, specializing in pharmaceutical glass packaging. A key milestone was the founding of SPAMI in 1971, which focused on designing and building high-speed precision machinery for glass tube containers, creating an integrated model. The company expanded internationally through acquisitions and greenfield projects, launching its pre-sterilized EZ-fill® syringes in 2007 and going public on the NYSE in 2021 under the ticker STVN.
- "Street Stereotype"
- Stevanato Group is generally perceived by investors and analysts as a 'picks and shovels' play on the growth of injectable drugs, particularly biologics and self-administered medicines. The market views it as a high-quality, family-influenced business with a strong competitive position in high-precision pharmaceutical packaging. There's a focus on its integrated model (providing both containment/delivery solutions and the machinery to produce them) as a key competitive advantage. However, there are also concerns regarding the slower-than-anticipated turnaround of its Engineering segment and potential impacts from the rise of oral GLP-1 therapies on its injectable-focused business. Analyst consensus is a 'Moderate Buy'.
- Subsidiaries On Linked In*
- Ompi, Balda, Spami, Optrel, InnoScan, SVM.
- Customer Sectors & Example Clients
- Stevanato Group's customers are primarily in the pharmaceutical, biotechnology, and life sciences industries. They serve companies developing and manufacturing small molecules, highly sensitive drugs, vaccines, RNA-based drugs, GLP-1 and peptides, and monoclonal antibodies (mAbs) and Antibody-Drug Conjugates (ADCs). While specific client names are not explicitly stated, the company mentions working with 'big international clients,' 'bio customer,' and a 'leading manufacturer for use with a GLP-1 biosimilar for type 2 diabetes.' Given their market position and product focus, it's highly probable their clients include major global pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) such as Eli Lilly, Novo Nordisk (for GLP-1s), and other top-tier biotech firms.
- New Customers / Segments They'Re Targeting
- Stevanato Group is actively targeting the broader global market for injectable biologics and biosimilars, beyond GLP-1s. They are focused on increasing their participation in other injectable biologics, with a 40% increase in customers ordering premium ranges (Alba and Nexa platforms) for biologic applications unrelated to GLP-1s in fiscal 2025. The company is also expanding its contract manufacturing activities for large device programs for a key U.S. customer, with commercial activities expected to begin in late 2026 or early 2027. Their strategy is to be a partner for the pharmaceutical industry in everything related to biologics, especially where injection and self-administration are required.
- Supply Chain And Sourcing Geographies
- Stevanato Group's supply chain includes manufacturing facilities in Europe, North America, and Asia. Key production sites are located in Piombino Dese and Latina in Italy, Bratislava in Slovakia, Monterrey in Mexico, and Zhangjiagang in China. They are also building a new plant in Sete Lagoas, Brazil. Significant investments are being made to expand capacity for high-value solutions in Fishers, Indiana (United States) and Latina, Italy, to meet rising global demand. The Fishers facility is intended to mirror the capabilities in Europe, particularly for EZ-fill technology, and to serve as a domestic supply chain for U.S. clients. They have also consolidated offices in Denmark and moved visual inspection activities to Italy, acquiring a new location in Bologna, Italy, to access strong technical talent.
- Sales Geographies And Expansion Plans
- Stevanato Group sells its products globally. The company has a global footprint which provides supply chain security to its customers. Specific regions mentioned for growth and customer engagement include the United States, Europe, and APAC (Asia-Pacific) for biosimilars. The investments in Fishers, Indiana, are aimed at serving the domestic United States market, while Latina, Italy, serves regional and national customers. The company is focused on expanding its presence in the broader global market for injectable biologics and biosimilars.
- How Key Themes May Help/Hurt
- The buildout of 'GLP-1 Equip/Distrib' is a significant tailwind for Stevanato Group. The company is already a market leader in high-value products for GLP-1s, with revenue from GLP-1s accounting for approximately 19% to 20% of total company revenue in fiscal 2025, growing more than 50% compared to 2024. They expect GLP-1s to serve as a meaningful tailwind as demand continues to grow, projecting mid-teens growth for GLP-1s in 2026. The Nexa syringe is their fastest-growing product, driven primarily by GLP-1s, and they are expanding capacity for EZ-fill cartridges to meet rising demand, partly due to new pen injector formats and biosimilar growth in APAC. While oral GLP-1 treatments are emerging, Stevanato Group believes injectables will remain the preferred format for treatment, representing about 70% of the market, with orals enabling market expansion rather than cannibalization. The increasing number of patients and new opportunities for Nexa syringes, EZ-fill cartridges, and device platforms will continue to boost their biological revenue.
3 Main Long-Term Bull Details
- Robust Demand for High-Value Solutions (HVS) in Biologics and GLP-1s: Stevanato Group is experiencing strong, sustained growth in its HVS portfolio, which represented 46% of total company revenue in fiscal 2025 and 49% in Q4 2025. This is primarily fueled by demand for Nexa syringes and EZ-fill vials/cartridges, especially for injectable biologics and GLP-1s, including a significant share of the GLP-1 market. The company expects GLP-1s to remain a meaningful tailwind with mid-teens growth in 2026.
- Strategic Capacity Expansions and Operational Leverage: The company's significant capital investments in its Fishers (US) and Latina (Italy) facilities are effectively ramping up, adding crucial capacity for high-value products like Nexa syringes and EZ-fill cartridges. These investments are aligning with customer demand trends and are expected to lead to increased operating leverage and improved financial performance as production scales.
- Integrated End-to-End Solutions and Market Leadership in Injectables: Stevanato Group offers a unique integrated model, providing both drug containment/delivery solutions and the specialized machinery to produce them. This 'one-stop-shop' approach, combined with market leadership in areas like pre-sterilized vials and syringes, creates strong customer stickiness, raises barriers to entry, and allows them to support customers across the entire drug lifecycle, particularly for the growing injectable biologics market.
3 Main Long-Term Bear Details
- Slower-than-Expected Recovery in the Engineering Segment: The Engineering segment continues to underperform, with revenue declining 23% in Q4 2025 and expected to decline by mid-single to low double digits in 2026. While optimization efforts are underway, converting the healthy pipeline into new orders has been slower than anticipated, impacting overall profitability and taking longer to return to historical performance levels.
- Foreign Currency Headwinds and Tariff Costs: The company faced foreign currency translation as a headwind throughout fiscal 2025, with a higher impact in the second half, and expects it to be a headwind of approximately EUR 18 million for fiscal 2026. While efforts are made to transfer tariff effects to customers, these external pressures can temper margins and negatively impact reported revenue and profitability.
- Potential Market Shifts and Competitive Pressures: While the company is confident in the continued dominance of injectable GLP-1s, the potential for oral GLP-1 therapies to gain significant market share could introduce uncertainty. Additionally, the market for GLP-1s is expected to evolve with different commercial and supply chain strategies among originators, biosimilar launches, and next-generation incretins, requiring continuous adaptation and potentially intensifying competition.
- Competitors And Differentiation
- Stevanato Group operates in a competitive market with other major players like Gerresheimer and Schott Pharma. Their differentiation strategy is centered on providing an integrated value proposition, offering a comprehensive portfolio from primary packaging to platform drug delivery devices. They emphasize their deep expertise, global footprint, and long-standing commitment to science and technology-driven innovation. The company's unique integrated model, which provides both drug containment/delivery solutions and the specialized machinery to produce them, creates strong customer stickiness and raises barriers to entry. They also highlight the quality of their products, such as the high mechanical resistance of their Nexa platform, which is ideal for auto-injectors and can be produced at scale.
- Recent Performance & What The Market'S Focused On
- Stevanato Group finished fiscal 2025 with a solid fourth quarter, leading to positive full-year performance and positive momentum into 2026. For fiscal 2025, total company revenue increased by 9% at constant currency rates and 7% on a reported basis compared with 2024. The Biopharmaceutical and Diagnostic Solutions (BDS) segment delivered double-digit top-line growth, driven by a 29% increase in high-value solutions, which represented 46% of total company revenue. This offset an expected revenue decline from the Engineering segment. GLP-1s accounted for 19% to 20% of total company revenue in 2025, growing over 50% year-over-year. For Q4 2025, total company revenue grew 7% at constant currency and 5% on a reported basis to $346.5 million. High-value solutions grew 31% and represented approximately 49% of total company revenue in the quarter. Gross profit margin increased 120 basis points to 30.9%, driven by a favorable mix of high-value solutions, improvements in new facilities, and an improved vial market, partially offset by tariffs and foreign currency. For 2026, the company expects revenue in the range of EUR 1.260 billion to EUR 1.290 billion, with high-value solutions ranging between 47% to 48% of total company revenue. The BDS segment is expected to grow high single to low double digits, while the Engineering segment is expected to decline by mid-single to low double digits. GLP-1 growth is projected to be in the mid-teens for 2026. The market is focused on the continued robust growth of high-value solutions, particularly for GLP-1s and other biologics, and the successful ramp-up of capacity at the Fishers and Latina facilities. Investors are also closely watching the progress of the Engineering segment's optimization efforts and its return to historical performance, as well as the impact of foreign currency headwinds. The long-term evolution of the GLP-1 market, including the balance between injectables and orals, is also a key area of interest.
- Brands And Revenue Segments
- Stevanato Group operates with two main operational divisions: Biopharmaceutical and Diagnostic Solutions (BDS) and Engineering. **Brands:** * Nexa (syringes) * Alba (syringes) * EZ-fill (syringes, cartridges, vials) * Alina (pen) * Vertiva * Fina * MAVIS * Ompi (ready-to-use glass containers and bulk primary packaging) * Balda (plastics solutions) * Spami, Optrel, InnoScan, SVM (Engineering Systems) **Revenue Segments:** * **Biopharmaceutical and Diagnostic Solutions (BDS):** This segment is the primary revenue driver, offering drug containment and delivery systems like syringes, vials, and cartridges, especially for biologics. In fiscal 2025, this segment delivered double-digit top-line growth. For Q4 2025, BDS revenue was EUR 307.1 million, representing approximately 88.6% of total company revenue. High-value solutions, a key component of BDS, represented 46% of total company revenue for fiscal 2025 and 49% for Q4 2025. * **Engineering:** This segment supplies glass forming, visual inspection, assembly, and packaging machinery. This segment experienced an expected revenue decline in fiscal 2025. For Q4 2025, Engineering segment revenue was EUR 39.4 million, representing approximately 11.4% of total company revenue.
Bull / Bear DetailsStevanato Group remains a compelling investment as of 2026-03-07, driven by robust demand for high-value solutions in its Biopharmaceutical and Diagnostic Solut
Thesis
Stevanato Group remains a compelling investment as of 2026-03-07, driven by robust demand for high-value solutions in its Biopharmaceutical and Diagnostic Solutions (BDS) segment, particularly for biologics and GLP-1s. Strategic capacity expansions in the US and Italy are ramping up, supporting future growth and margin expansion. While the Engineering segment faces continued near-term challenges and currency headwinds persist, strong execution in high-value products and market tailwinds position STVN for sustained long-term growth.
Bull case
Stevanato Group continues to demonstrate strong, sustained growth in high-value solutions (HVS), which grew 31% in Q4 2025 and represented 49% of total revenue. This is fueled by demand for Nexa syringes and EZ-fill cartridges for injectable biologics, including GLP-1s, and a 40% increase in non-GLP-1 biologic customers in 2025, diversifying growth drivers.
The company's significant capital investments in its Fishers (US) and Latina (Italy) facilities are effectively ramping up, with prefilled syringe capacity running at approximately full capacity in 2025 and continued robust demand expected in 2026. These expansions add crucial capacity for high-value products and align with industry onshoring trends, creating long-term opportunities.
Stevanato is guiding for modest margin expansion in 2026, driven by a favorable mix of high-value solutions and improving operational performance at its new Latina and Fishers facilities as they scale production. The RTU vial market also saw a 6% growth in 2025 and is expected to grow mid-to-high single digits in 2026, further contributing to profitability.
Bear case
The Engineering segment continues to underperform, with revenue declining 23% in Q4 2025 and an expected mid-single to low double-digit decline in 2026. Despite operational improvements, slower order intake and longer sales cycles for complex lines are delaying its return to historical performance, acting as a drag on overall company growth and profitability.
While GLP-1s remain a significant tailwind, their growth is normalizing from over 50% in 2024 to an expected mid-teens in 2026. This deceleration, following an initial surge, indicates a more mature growth phase for this specific category, potentially impacting the overall top-line growth rate compared to prior periods.
Foreign currency translation is expected to remain a headwind, with an anticipated impact of approximately EUR 18 million on revenue for fiscal 2026, with about 30% of this affecting margins. Additionally, the new Latina and Fishers facilities, while ramping up, are still dilutive to corporate margins, and Fishers' full profitability will take longer to achieve.
Bull / Bear Case
- Bear Case
- The company faces headwinds primarily from its Engineering segment, which saw a 23% revenue decline in Q4 2025 and is projected to decline by mid-single to low double-digits in 2026. This underperformance is attributed to slower order intake and extended sales cycles for complex lines, delaying its return to historical profitability. While GLP-1s remain a tailwind, their growth is normalizing from over 50% in 2024 to an expected mid-teens in 2026, indicating a more mature growth phase. Additionally, foreign currency translation is anticipated to be a significant headwind, impacting 2026 revenue by approximately EUR 18 million and affecting margins. The new Latina and Fishers facilities, despite ramping up, are still dilutive to corporate margins, with Fishers' full profitability taking longer to achieve.
- Bull Case
- Stevanato Group is poised for continued growth, driven by robust demand for its high-value solutions (HVS), which grew 31% in Q4 2025 and now represent 49% of total revenue. This growth is fueled by injectable biologics, including GLP-1s, and a 40% increase in non-GLP-1 biologic customers in 2025, diversifying revenue streams. Strategic capacity expansions in Fishers, US, and Latina, Italy, are effectively ramping up, with prefilled syringe capacity running near full utilization and strong demand anticipated for 2026. The company expects modest margin expansion in 2026 due to a favorable HVS mix and improving operational performance at these new facilities, further supported by a recovering RTU vial market.
- More Compelling & Why
- Bull. The current P/E ratio of STVN, around 25-29x, is significantly lower than its 3-year historical average of 45.34x and the US Life Sciences industry average of 35.2x. This undervaluation, despite robust growth in high-value solutions (HVS) and strategic positioning in the expanding biologics and GLP-1 markets, makes the bull case more compelling. The strong performance of the core Biopharmaceutical and Diagnostic Solutions segment is effectively offsetting the acknowledged challenges in the Engineering segment. My view would flip if HVS growth significantly decelerates below expectations or if the Engineering segment's decline worsens, materially impacting overall profitability and free cash flow generation.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| High-Value Solutions (HVS) Revenue Contribution and Growth | HVS is the primary driver of revenue growth and margin expansion, reflecting the company's successful strategic pivot towards premium offerings in biologics and self-administration. Sustained performance validates the investment thesis. | HVS revenue as a percentage of total company revenue (2026 guidance: 47-48%); Y/Y growth rate of HVS revenue (2025 Q4 growth: 31%). | Bullish: HVS revenue consistently at or above 48% of total revenue and Y/Y growth exceeding low double-digits (constant currency). Bearish: HVS revenue falling below 47% of total revenue or significant deceleration in Y/Y growth. | Company earnings calls and press releases (quarterly), investor presentations. | Industry reports from market research firms (e.g., IQVIA, Grand View Research) on biologics and injectable drug delivery market growth. | IQVIA: Market data on biologics drug launches and injectable device adoption rates. |
| Profitability and Commercial Ramp-up of Latina and Fishers Facilities | These new facilities are critical for expanding high-value solutions capacity. Their path to profitability and full commercialization will significantly impact overall corporate margins, free cash flow, and the ability to meet demand. | Management commentary on the financial performance of Latina and Fishers (currently dilutive); progress on customer validations; commencement of commercial activities for the first device program at Fishers (expected end of 2026 or early 2027). | Bullish: Latina and Fishers achieving positive gross profit margins faster than anticipated; commercial activities at Fishers starting earlier than expected or with higher initial volumes. Bearish: Delays in achieving profitability for either facility; setbacks in customer validations or the start of commercial activities at Fishers. | Company earnings calls and press releases (quarterly), investor presentations. | ||
| Engineering Segment Order Intake and Revenue Trend | The Engineering segment's underperformance and slower order conversion continue to be a drag on overall company performance, despite operational improvements. A turnaround is crucial for long-term stability and margin recovery. | Management commentary on order intake conversion rates and pipeline strength; Y/Y revenue growth for the Engineering segment (2026 guidance: mid-single digit to low double-digit decline); gross profit margin for the Engineering segment. | Bullish: Engineering segment revenue decline moderating faster than expected or turning positive Y/Y; significant improvement in gross profit margin. Bearish: Continued Y/Y revenue decline at the higher end of the guidance range or stagnant/declining gross profit margins. | Company earnings calls and press releases (quarterly), investor presentations. | Company career pages: Job postings for 'sales engineer' or 'project manager' in the Engineering segment could indicate future activity. | Thinknum: Job postings for Stevanato Group's Engineering division (e.g., 'sales', 'project management') 30-day growth. |
| GLP-1 Revenue Growth Rate and Product Mix Evolution | GLP-1s were a significant tailwind in 2025, and their continued growth rate and the shift in product formats (syringes vs. cartridges) will heavily influence Stevanato's top-line performance and future capacity investments. | GLP-1 revenue growth rate for 2026 (guidance: mid-teens); commentary on the relative demand for Nexa syringes versus EZ-fill cartridges for GLP-1 applications, especially beyond 2026. | Bullish: GLP-1 revenue growth exceeding mid-teens in 2026 or stronger-than-expected demand for EZ-fill cartridges for GLP-1s beyond 2026. Bearish: GLP-1 revenue growth falling below mid-teens or significant cannibalization of Nexa syringes by oral GLP-1s. | Company earnings calls and press releases (quarterly), investor presentations. | Google Trends: Search volume for 'GLP-1 drugs' or specific drug names (e.g., 'Wegovy', 'Ozempic'). | Symphony Health: Prescription data for GLP-1 drugs; EvaluatePharma: Market share and forecast data for GLP-1 drug delivery devices. |
| RTU Vial Demand and Growth | The recovery in the vial market, particularly for Ready-to-Use (RTU) vials, contributes to the BDS segment's performance and overall revenue growth. Sustained demand indicates broader market health and operational efficiency. | Y/Y revenue growth for RTU vials (2026 expectation: mid-to-high single-digit growth); management commentary on inventory levels and demand trends for vials. | Bullish: RTU vial revenue growth exceeding mid-to-high single-digits in 2026; strong order intake for RTU vials. Bearish: Deceleration in RTU vial revenue growth or renewed concerns about customer inventory levels. | Company earnings calls and press releases (quarterly), investor presentations. | Industry association reports (e.g., PDA, ISPE) on pharmaceutical packaging trends and vial demand. | Transparency Market Research: Global pharmaceutical packaging market reports, including vial segment analysis. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| High-Value Solutions Revenue | High-Value Solutions are the primary driver of Stevanato Group's revenue growth and margin expansion, reflecting its strategic shift towards premium offerings in biologics and self-administration. Continued strong performance indicates successful execution of its strategy. | 31% |
| Total Company Revenue | Total Company Revenue is a fundamental indicator of Stevanato Group's overall business health and market demand. It reflects the combined performance of its segments and the effectiveness of its growth strategies in a dynamic market. | 5% |
| GLP-1 Revenue Growth | GLP-1s served as a significant tailwind in 2025 and are expected to continue driving growth. This metric is crucial for understanding the company's ability to capitalize on this high-growth therapeutic area and its impact on overall performance. | 50% |
Key QuestionsWill Stevanato Group achieve its mid-teens GLP-1 revenue growth target for 2026, and will the High-Value Solutions segment maintain its projected contribution o
Will Stevanato Group achieve its mid-teens GLP-1 revenue growth target for 2026, and will the High-Value Solutions segment maintain its projected contribution of 47-48% of total revenue, effectively driving overall top-line growth?
- Question 2
Can the Engineering segment demonstrate a tangible improvement in order intake conversion and moderate its revenue decline faster than the mid-single to low double-digit expectation for 2026, signaling a clearer path to recovery?
- Question 3
How quickly will the Latina and Fishers facilities improve their gross profit margins and reduce their dilutive impact on corporate profitability, particularly given the ongoing ramp-up, customer validations, and the delayed start of commercial activities for the first device program at Fishers?
Rerating Thresholds
| Metric | What'S Needed For Rerating | Why It Matters | Earnings Date |
|---|---|---|---|
| High-Value Solutions Revenue | Stevanato Group's High-Value Solutions Revenue needs to consistently represent above 44% of total revenue for fiscal year 2025, ideally maintaining or exceeding the 49% achieved in Q3 2025. Concurrently, the year-over-year growth of High-Value Solutions Revenue must remain above 40%, ideally maintaining or exceeding the 47% growth seen in Q3 2025. | Hitting these thresholds validates Stevanato's strategic shift towards premium integrated solutions, demonstrating sustained execution in high-growth biologics and self-administration markets. This signals continued margin expansion and strengthens its competitive position, driving a positive re-evaluation of its long-term valuation. | 2026-03-04 |
| Adjusted Diluted EPS | For Stevanato Group S.p.A. (STVN) to rerate higher, the Adjusted Diluted EPS for Q4 2025 needs to hit at least €0.21-€0.22. This would represent a meaningful beat against the current analyst consensus estimate of approximately €0.19-€0.20 for Q4 2025 and exceed the high end of the company's reiterated full-year 2025 guidance of €0.50-€0.54. Given Q1-Q3 2025 Adjusted Diluted EPS totaled €0.35, a Q4 EPS of €0.19 is needed to meet the high end of the full-year guidance. Exceeding this by a notable margin, similar to peer West Pharmaceutical Services (WST) which beat EPS estimates by over 11% in Q4 2025, would be crucial. | Hitting this Adjusted Diluted EPS threshold for Q4 2025 would signal robust execution, particularly in the high-value solutions segment, and demonstrate effective management of operational challenges like the Engineering segment's underperformance and foreign currency headwinds. This would validate the investment thesis around strong demand for biologics and GLP-1 biosimilars, alleviate concerns about cash flow, and could lead to an improved competitive position and a higher valuation multiple for the stock. | 2026-03-04 |
| Total Revenue | Stevanato Group S.p.A. (STVN) would likely need to report Q4 2025 total revenue growth significantly above the 9% year-over-year seen in Q3 2025, ideally reaching low double-digits (e.g., 12%+ year-over-year) and beating the analyst consensus estimate of approximately $385.5 million for the quarter. This acceleration should be driven by continued robust growth in High-Value Solutions (HVS), with HVS revenue growth exceeding 40% year-over-year and maintaining its contribution to total revenue at or above 49%. Additionally, a clear indication of a moderating decline or a path to recovery for the Engineering segment, coupled with strong 2026 revenue guidance that surpasses current growth rates and potentially peer averages (e.g., exceeding West Pharmaceutical Services' 5-7% organic growth forecast), would be crucial for a rerating. | Hitting these revenue thresholds matters because it would signal that Stevanato Group is successfully leveraging demand for high-value solutions and GLP-1 biosimilars, offsetting the drag from the Engineering segment. This demonstrates strong execution of its growth strategy, justifying a higher valuation, improving competitive positioning against peers, and exceeding market expectations for sustained growth and profitability. | 2026-03-04 |
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Scaling High-Value Solutions Capacity and Execution**: Management is focused on leveraging strategic growth investments in facilities like Latina and Fishers to expand capacity for high-value solutions (e.g., Nexa syringes, EZ-fill cartridges) and ensure successful customer validations and commercial production ramp-up. They emphasized running at "approximately full capacity" for prefilled syringes in 2025 and the continued positive momentum into 2026. 2. **Optimizing and Repositioning the Engineering Segment**: Management is dedicated to improving the Engineering segment's performance through optimization efforts, rightsizing operations, streamlining processes, and strengthening sales and marketing. While acknowledging slower order intake and a longer recovery than expected, they are focused on securing new, more standardized orders and leveraging operational improvements. 3. **Capitalizing on the GLP-1 and Broader Biologics Market**: A significant focus is on maintaining and expanding their leadership in the GLP-1 market, which was a major tailwind in 2025 and is expected to continue growing. Beyond GLP-1s, they are focused on increasing participation in other injectable biologics with their premium high-value product portfolio, aiming to be a key partner for all injection-based therapies. | The overall takeaway from the call is one of cautious optimism. Stevanato Group delivered solid financial results for Q4 and full-year 2025, driven by robust double-digit growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and strong performance in high-value solutions, particularly from GLP-1s. Management expressed confidence in their strategic execution, capacity expansions in Latina and Fishers, and their positioning in the growing biologics and self-administration markets. However, the tone was notably cautious regarding the Engineering segment, acknowledging that its recovery and order intake are taking longer than expected, despite operational improvements. Currency headwinds are also anticipated for 2026. The company provided 2026 guidance reflecting continued high-value growth but a more muted outlook for Engineering, with an expectation of modest margin expansion and breakeven to positive free cash flow. | For the third quarter of 2025: * Total revenue increased by 9% year-over-year. * Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 14% year-over-year. * Engineering segment declined by 19% year-over-year. * Revenue from high-value solutions grew 47%. * Revenue from other containment delivery solutions decreased by 10%. | 1. **GLP-1 Growth Outlook for 2026**: Analysts questioned why the 2026 GLP-1 growth guidance (mid-teens) seemed conservative after 50% growth in 2025. Management responded that 2025 saw a "massive preparation of the supply chain" and an "initial surge," and a mid-teens growth in 2026 is a "realistic number" as products go commercial, followed by a "period of normalization where growth slows a bit." They also noted that beyond 2026, the market configuration (originator vs. biosimilar, pen vs. auto-injector) is still evolving. 2. **Engineering Segment Recovery and Order Intake**: Analysts pressed on the disappointing 2026 guidance for the Engineering segment and the reasons behind the low order intake. Management explained that while operational progress is strong (e.g., doubled site acceptance rates), the sales cycle for these technical lines is longer than anticipated, leading to delayed order confirmations. They reiterated that the underlying pharmaceutical market demand for new machines, especially for biologics and self-administration, is "robust" and the "pipeline is healthy," with a strong medium-term outlook. 3. **High-Value Solutions Capacity vs. Demand and Margin Expansion**: Analysts inquired about the utilization and capacity constraints for high-value solutions, particularly with the ramp-up of Fishers and Latina, and the drivers of margin expansion for 2026. Management confirmed that they ran "approximately full capacity" in 2025 for prefilled syringes and expect robust demand to continue playing a role in 2026. For margins, they guided for 0-30 basis points expansion, citing headwinds from higher depreciation and currency, but tailwinds from improving financial performance at Latina and Fishers as they scale, and a better project mix in Engineering. | For the fourth quarter of 2025: * Total company revenue increased by 7% at constant currency and 5% on a reported basis. * Biopharmaceutical and Diagnostic Solutions (BDS) segment revenue increased by 13% at constant currency and 10% on a reported basis. * Engineering segment revenue decreased by 23%. * Revenue from high-value solutions grew 31%, representing approximately 49% of total company revenue. * Revenue from other containment and delivery solutions (within BDS) decreased by 9%. |
· 2025Q3 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Executing Strategic Roadmap and Capacity Expansion**: Management is focused on leveraging and scaling up growth investments in capacity expansion to meet increased demand for high-value products, particularly Nexa syringes and EZ-fill vials and cartridges, across their Fishers and Latina facilities. 2. **Optimizing the Engineering Segment**: Management is actively working on a business optimization plan for the Engineering segment, strengthening the sales organization, refining commercial processes, and repositioning the segment for stronger profitability, acknowledging that it will take more time to return to historical performance levels. 3. **Meeting Demand for Injectable Biologics and Self-Administration**: The company is focused on meeting the demands of high-growth markets like injectable biologics, which require premium containment and delivery solutions, and supporting the increasing trend towards self-administration of medicine with products like EZ-fill cartridges. | The overall takeaway from the call is one of cautious optimism. The company delivered solid third-quarter financial results, exceeding expectations primarily driven by strong performance in the BDS segment and record growth in high-value solutions. Management reiterated its full-year 2025 guidance despite foreign currency headwinds and challenges in the Engineering segment, demonstrating confidence in their strategic roadmap and the ability of high-value solutions growth to offset these impacts. The tone was positive regarding the BDS segment, high-value solutions, and the long-term market tailwinds from biologics and self-administration. However, there was a cautious tone regarding the Engineering segment, acknowledging that its recovery will take more time than initially expected, despite ongoing optimization efforts. | For Q2 2025, the Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 10% year-over-year. The Engineering segment declined by 2% year-over-year in Q2 2025. | 1. **Q3 Outperformance and High-Value Solutions Growth**: Analysts inquired about the $10 million outperformance in Q3 and the drivers of strong high-value solutions growth. Management responded that the $10 million was an acceleration of Q4 sales to accommodate customer supply chain needs, primarily in high-value solutions like high-performance syringes. They attributed high-value growth to strong demand for Nexa syringes, traction in Alba syringes, and a recovery in sterile vials. 2. **Engineering Segment Recovery and Timeline**: Analysts pressed on the timeline for the Engineering segment's return to growth and whether it could grow in 2026. Management acknowledged that while operational progress is being made, converting the healthy pipeline into new orders has been slower than anticipated, mainly due to key customers awaiting final acceptance tests and reevaluating manufacturing footprints. They believe the long-term demand landscape remains strong due to industry expansion and technology upgrades. 3. **Biosimilar Opportunity, especially GLP-1s**: Analysts asked about the broader picture of biosimilars, specifically GLP-1s, and their contribution to Stevanato's growth. Management explained that biosimilars help enlarge revenue for the industry, and Stevanato is deeply involved with both originator and biosimilar programs across its high-value product platform, including Nexa syringes and ready-to-fill cartridges. They view this as a net positive effect, translating into more orders for their products. | Total revenue increased by 9% year-over-year. The Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 14% year-over-year. The Engineering segment declined by 19% year-over-year. Revenue from high-value solutions grew 47%. Revenue from other containment delivery solutions decreased by 10%. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Key signals point to expanding eligible market: strong growth in high-value solutions driven by Nexa syringes and EZ-fill vials (approximately 46-47% growth) and a shift to ready-to-use platforms that support self-administration; GLP-1 biosimilar activity and broader biologics demand supported by ready-to-use cartridges and autoinjector formats; accelerating capacity build in the U.S. (onshoring) with major pharma players investing in U.S. manufacturing to meet higher quality standards and stricter regulations (e.g., Annex 1); ongoing capital investments at Fishers and Latina to scale Nexa, EZ-fill and related lines, with continued growth expected through 2026 and beyond to meet rising biologics demand. | Competition dynamics center on biosimilars' growing role and the need for integrated, high-value packaging and delivery solutions. Biosimilars can broaden revenue across originator and biosimilar programs (roughly 70% originator, 30% biosimilar when patents expire), and management emphasized maintaining leadership across Nexa, Alba and EZ-fill platforms. The company noted currency headwinds and tariff costs, implying pricing and regulatory pressures that could affect margins. The ambition to become a fully integrated high-value solutions provider suggests differentiation but also intensifies competition with peers expanding into end-to-end systems (e.g., larger players in packaging and devices). | Industry trends include robust growth in injectable biologics, a shift toward ready-to-use platforms, self-administration, and regulatory tightening (Annex 1). Onshoring of manufacturing toward the United States is accelerating as customers reassess footprints. Major capacity investments at Fishers and Latina to support biologics and auto-injector ecosystems, plus new lines and clean rooms for Alina Pen and broader CMO initiatives, indicate a multi-year capacity build and increased focus on high-value biologics packaging and devices; sustainability ESG milestones are also part of industry evolution. | Outlook remains constructive: 2026 guidance centers High-Value Solutions at 47-48% of revenue; currency headwinds expected but offset by organic growth; continued capacity ramp at Fisher and Latina to sustain longer-term growth toward 2028; investments in EZ-fill, Nexa, Alba, and ready-to-fill cartridges, plus the new Germany clean room for Alina Pen; potential upside from broader CMO initiatives and expanded biologics applications. | GLP1 | Biologics growth, ready-to-use platforms, self-administration, onshoring manufacturing, and end-to-end integration in packaging and devices; regulatory tightening and tariff headwinds; biosimilars expansion; capacity expansion across US and Europe. | We remain on track to meet our 2025 guidance. The industry expands its capacity to satisfy growing demand for injectable biologics and devices. EZ-fill cartridges are setting a new standard. We are well-positioned to meet evolving industry demands and support patient-centric solutions. | Foreign currency translation was a headwind. Certain tariff costs were not mitigated. The current slowdown in order flow is not permanent and will take time to recover. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Key signals point to expanding eligible market: (1) strong growth in high-value solutions driven by Nexa syringes and EZ-fill vials (46-47% growth noted) and a shift to ready-to-use platforms that support self-administration; (2) GLP-1 biosimilar activity and broader biologics demand supported by a focus on ready-to-use cartridges and autoinjector-compatible formats; (3) accelerating capacity build in the U.S. (onshoring) with major pharma players investing in U.S. manufacturing to meet higher quality standards and stricter regulations (e.g., Annex 1); (4) ongoing capital investments at Fisher and Latina to scale Nexa, EZ-fill and related lines, with expectations of continued growth through 2026 and beyond to meet rising biologics demand. | Competition dynamics center on the growing role of biosimilars and the need for integrated high-value packaging and delivery solutions. Management stressed that biosimilars can broaden revenue opportunities across originator and biosimilar products (roughly 70% originator, 30% biosimilar when patents expire) and highlighted the importance of maintaining leadership across Nexa, Alba and EZ-fill platforms. They also noted a cautious outlook due to currency headwinds and tariff costs, implying pricing and regulatory pressures that could affect margins. The goal to become a fully integrated high-value solutions provider implies competitive differentiation but also intensifies competition with peers expanding into end-to-end systems. | Industry trends include strong growth in injectable biologics, a broad shift to ready-to-use platforms, self-administration, and regulatory tightening (Annex 1). The transcript reinforces onshoring as customers reevaluate manufacturing footprints toward the United States, with substantial investments in new capacity and clean rooms to support biologics and auto-injector ecosystems. Firms are prioritizing high-value, integrated solutions and expanding manufacturing networks to meet demand while pursuing sustainability (ESG milestones). | Prospects remain positive with guidance reaffirmed for 2025. High-value solutions are expected to represent 43–44% of revenue (up from prior 40–42%), currency headwinds anticipated but offset by organic growth, and ongoing capacity ramp at Fisher and Latina to support longer-term growth toward 2028 (aiming for full capacity and roughly $0.5B in revenue uplift). The company plans continued investment in EZ-fill, Nexa, Alba, and new lines for ready-to-fill cartridges, plus a new Germany clean room for Alina Pen and broader CMO initiatives, signaling a multi-year growth trajectory and potential upside into 2026 and beyond. | GLP1 | We remain on track to meet our 2025 guidance.; The industry expands its capacity to satisfy growing demand for injectable biologics and devices.; EZ-fill cartridges are setting a new standard.; We are well-positioned to meet evolving industry demands and support patient-centric solutions. | Foreign currency translation was a headwind.; Certain tariff costs were not mitigated.; The current slowdown in order flow is not permanent and will take time to recover; Getting the segment back to historical performance levels is going to take more time. | Strengthening the sales organization with fresh expertise and refining our commercial processes; reinforcing our commercial teams to support growth across high-value platforms and ready-to-use solutions. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Key signals point to expanding eligible market: (1) strong growth in high-value solutions driven by Nexa syringes and EZ-fill vials (46-47% growth noted) and a shift to ready-to-use platforms that support self-administration; (2) GLP-1 biosimilar activity and broader biologics demand supported by a focus on ready-to-use cartridges and autoinjector-compatible formats; (3) accelerating capacity build in the U.S. (onshoring) with major pharma players investing in U.S. manufacturing to meet higher quality standards and stricter regulations (e.g., Annex 1); (4) ongoing capital investments at Fisher and Latina to scale Nexa, EZ-fill and related lines, with expectations of continued growth through 2026 and beyond to meet rising biologics demand. | Competition dynamics center on the growing role of biosimilars and the need for integrated high-value packaging and delivery solutions. Management stressed that biosimilars can broaden revenue opportunities across originator and biosimilar products (roughly 70% originator, 30% biosimilar when patents expire) and highlighted the importance of maintaining leadership across Nexa, Alba and EZ-fill platforms. They also noted a cautious outlook due to currency headwinds and tariff costs, implying pricing and regulatory pressures that could affect margins. The goal to become a fully integrated high-value solutions provider implies competitive differentiation but also intensifies competition with peers expanding into end-to-end systems. | Industry trends include strong growth in injectable biologics, a broad shift to ready-to-use platforms, self-administration, and regulatory tightening (Annex 1). The transcript reinforces onshoring as customers reevaluate manufacturing footprints toward the United States, with substantial investments in new capacity and clean rooms to support biologics and auto-injector ecosystems. Firms are prioritizing high-value, integrated solutions and expanding manufacturing networks to meet demand while pursuing sustainability (ESG milestones). | Prospects remain positive with guidance reaffirmed for 2025. High-value solutions are expected to represent 43–44% of revenue (up from prior 40–42%), currency headwinds anticipated but offset by organic growth, and ongoing capacity ramp at Fisher and Latina to support longer-term growth toward 2028 (aiming for full capacity and roughly $0.5B in revenue uplift). The company plans continued investment in EZ-fill, Nexa, Alba, and new lines for ready-to-fill cartridges, plus a new Germany clean room for Alina Pen and broader CMO initiatives, signaling a multi-year growth trajectory and potential upside into 2026 and beyond. | GLP1 | We remain on track to meet our 2025 guidance.; The industry expands its capacity to satisfy growing demand for injectable biologics and devices.; EZ-fill cartridges are setting a new standard.; We are well-positioned to meet evolving industry demands and support patient-centric solutions. | Foreign currency translation was a headwind.; Certain tariff costs were not mitigated.; The current slowdown in order flow is not permanent and will take time to recover; Getting the segment back to historical performance levels is going to take more time. | Strengthening the sales organization with fresh expertise and refining our commercial processes; reinforcing our commercial teams to support growth across high-value platforms and ready-to-use solutions. |
Earnings ResultsHigh-Value Solutions Revenue represented approximately 49% of total company revenue, meeting the target for contribution to total revenue. However, the year-ove
| Metric | Prior Quarter | Rerating Trigger | Actual Reported | Hit Target? | Notes |
|---|---|---|---|---|---|
| High-Value Solutions Revenue | 47% | Stevanato Group's High-Value Solutions Revenue needs to consistently represent above 44% of total revenue for fiscal year 2025, ideally maintaining or exceeding the 49% achieved in Q3 2025. Concurrently, the year-over-year growth of High-Value Solutions Revenue must remain above 40%, ideally maintaining or exceeding the 47% growth seen in Q3 2025. | €171 million (31% y/y growth), representing approximately 49% of total company revenue. | Partially | High-Value Solutions Revenue represented approximately 49% of total company revenue, meeting the target for contribution to total revenue. However, the year-over-year growth of 31% for Q4 2025 was below the rerating trigger of above 40% (and the prior quarter's 47% growth), indicating a deceleration in growth for this segment. |
| Adjusted Diluted EPS | 17% | For Stevanato Group S.p.A. (STVN) to rerate higher, the Adjusted Diluted EPS for Q4 2025 needs to hit at least €0.21-€0.22. This would represent a meaningful beat against the current analyst consensus estimate of approximately €0.19-€0.20 for Q4 2025 and exceed the high end of the company's reiterated full-year 2025 guidance of €0.50-€0.54. Given Q1-Q3 2025 Adjusted Diluted EPS totaled €0.35, a Q4 EPS of €0.19 is needed to meet the high end of the full-year guidance. Exceeding this by a notable margin, similar to peer West Pharmaceutical Services (WST) which beat EPS estimates by over 11% in Q4 2025, would be crucial. | €0.18 | No | The adjusted diluted EPS of €0.18 for Q4 2025 fell short of the rerating trigger of at least €0.21-€0.22 and was also below the analyst consensus estimate of approximately €0.19-€0.20. This indicates a miss on profitability expectations for the quarter. |
| Total Revenue | 9% | Stevanato Group S.p.A. (STVN) would likely need to report Q4 2025 total revenue growth significantly above the 9% year-over-year seen in Q3 2025, ideally reaching low double-digits (e.g., 12%+ year-over-year) and beating the analyst consensus estimate of approximately $385.5 million for the quarter. This acceleration should be driven by continued robust growth in High-Value Solutions (HVS), with HVS revenue growth exceeding 40% year-over-year and maintaining its contribution to total revenue at or above 49%. Additionally, a clear indication of a moderating decline or a path to recovery for the Engineering segment, coupled with strong 2026 revenue guidance that surpasses current growth rates and potentially peer averages (e.g., exceeding West Pharmaceutical Services' 5-7% organic growth forecast), would be crucial for a rerating. | $346.5 million (5% y/y growth reported basis, 7% y/y growth constant currency) | No | Total company revenue of $346.5 million (5% y/y reported growth) missed the rerating trigger of 'significantly above 9% year-over-year' and 'ideally reaching low double-digits (e.g., 12%+ year-over-year)'. The reported revenue also fell short of the analyst consensus estimate of approximately $385.5 million. The Engineering segment's 23% revenue decline continued to be a drag on overall revenue. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-03-04 | Stevanato Group reported solid Q4 and FY25 results, driven by strong double-digit growth in high-value solutions, particularly Nexa syringes for GLP-1s. The company provided positive 2026 guidance, forecasting mid-teens GLP-1 growth and continued BDS segment strength, despite ongoing Engineering segment challenges. The stock's 4.62% rise, significantly outperforming the SPY, indicates the market perceived the results and outlook positively, aligning with the company's strategic focus on high-growth biologics. | Other | Bullish | False | +4.62% (vs SPY: +5.79%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| STVN_d69cac2b | throughout 2026 | 2026-01-01 | 2026-12-31 | Continued installation and customer validation of additional syringe lines at the Fishers facility. | This will increase capacity for high-value solutions, driving revenue growth and margin expansion as the facility scales and gains operating leverage. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_59f2379c | mid-2026 | 2026-05-01 | 2026-06-30 | Commencement of customer validations for the first vial lines at the Fishers facility. | This marks a critical step towards commercial production of vials at Fishers, contributing to high-value solution revenue and improving facility margins. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_bc850de3 | at the end of 2026 or early 2027 | 2026-10-01 | 2027-03-31 | Commencement of commercial activities for contract manufacturing of large device programs at the Fishers facility. | This represents a new revenue stream and leverages the company's capabilities in drug delivery devices, contributing to overall growth and diversification. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_5a8f34f7 | continue into 2026 | 2026-01-01 | 2026-12-31 | Continued scaling of commercial production for Nexa Syringes at the Latina facility. | Increased production capacity for high-demand Nexa syringes will drive revenue growth in high-value solutions and improve operating leverage at the Latina plant. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_ebb2649b | Preparations are underway for the next phase of EZ-fill cartridge production to meet the rising demand for ready-to-use cartridges. This next phase will be powered by our new R400 EZ-fill cartridge lines. | 2026-01-01 | 2026-12-31 | Ramp-up of the next phase of EZ-fill cartridge production at the Latina facility, utilizing new R400 EZ-fill cartridge lines. | This expansion directly addresses rising demand for ready-to-use cartridges, a high-value solution, contributing to revenue growth and strengthening the company's position in the self-administration market. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_f8023995 | in the coming quarters | 2026-01-01 | 2026-06-30 | Improved conversion of the Engineering segment's healthy pipeline into new orders. | A faster conversion rate would boost Engineering segment revenue, which has been declining, and improve its profitability, which is currently below expectations. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_ca09a557 | at the end of 2028 | 2028-10-01 | 2028-12-31 | Fishers facility reaching full production capacity and generating $0.5 billion in revenue. | Achieving full capacity at Fishers will significantly boost high-value solution revenue, improve overall company margins, and validate the strategic investment in the facility. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_b5165e86 | until 2028 | 2026-01-01 | 2028-12-31 | Addition of several hundred million in additional capacity for high-value products across various facilities. | This ongoing capacity expansion is crucial for meeting increasing customer demand for high-value solutions, supporting revenue growth, and maintaining market leadership in specialized drug containment and delivery. | Ticker | 2025-11-07 | earnings_transcript |
| STVN_2673ce4f | mid-teens growth for 2026 | 2026-01-01 | 2026-12-31 | Stevanato Group achieving mid-teens revenue growth from GLP-1 related products in fiscal year 2026. | GLP-1s are a significant revenue driver (19-20% of 2025 revenue), and achieving this growth is crucial for overall company performance and investor sentiment. | Ticker | 2026-03-04 | earnings_transcript |
| STVN_7fce4c2f | this year, we're going to install the first high-speed line forecast is way to fill, but the goal is to do the validation is yet to start to do commercial revenue in the beginning of 2027 | 2026-03-07 | 2027-03-31 | Successful installation, validation, and commencement of commercial revenue generation from new high-speed EZ-fill cartridge lines at the Latina facility. | This expansion is critical to meet rising global demand for cartridges, support new pen injector formats and biosimilars, and drive future high-value solutions growth and margin expansion. | Ticker | 2026-03-04 | earnings_transcript |
| STVN_b86df9cd | line installations and customer validation activities are expected to continue all year | 2026-01-01 | 2026-12-31 | Continued progress and successful completion of line installations and customer validation activities at the Fishers facility throughout 2026. | This is essential for ramping up capacity for high-value syringes and other products in the US, meeting customer demand, and improving the facility's financial performance. | Ticker | 2026-03-04 | earnings_transcript |
| STVN_ced6ef02 | commercial activities to begin at the end of 2026 or early 2027 for the first device program | 2026-10-01 | 2027-03-31 | Commencement of commercial activities for the first large device program at the Fishers facility for a key U.S. customer. | This represents a new significant revenue stream from contract manufacturing activities, leveraging integrated capabilities and high-value solutions for a major client. | Ticker | 2026-03-04 | earnings_transcript |
| STVN_2f9596ce | Converting opportunities into new firm orders has been slower than we anticipated and getting the business back to historical performance is taking longer than we expected | 2026-03-07 | 2027-03-07 | Improvement in the Engineering segment's order intake conversion rate and progress towards returning to historical performance levels. | The Engineering segment's underperformance is a drag on overall results and margins; improved order intake and execution are crucial for its long-term success and contribution to the company. | Ticker | 2026-03-04 | earnings_transcript |
| STVN_90225f22 | the GLP-1 in the next decade, it will continue to be a powerful tailwinds | 2027-01-01 | 2036-12-31 | The evolving landscape of the GLP-1 market, including the mix of injectables vs. orals, originator vs. biosimilar strategies, and new product launches. | This evolution will determine the long-term demand trajectory for Stevanato's high-value syringes, cartridges, and devices, impacting its sustained growth and market leadership in this critical therapeutic area. | Theme | 2026-03-04 | earnings_transcript |